Yabing Cao
Extranodal Natural Killer/T-cell Lymphoma (ENKTCL)-associated Hemophagocytic Syndrome (HPS) is a rare and fatal disease. Chemotherapy was commonly used but the efficacy was dismal. Although immunotherapy with immune checkpoint inhibitors was effective in NK/T cell lymphoma, the use of immunotherapy in introduction treatment of HPS was controversial with concern on side effects. We report a case of HPS who was treated with immunotherapy instead of chemotherapy for HPS. The patient achieved complete remission, confirming that immunotherapy is an effective treatment approach for patients with ENKTCL-associated HPS.